Biomind Labs Inc.’s $6 Million Private Placement

Aird & Berlis acted for Biomind on the transaction.

Biomind Labs Inc. (formerly Crosswinds Holdings Inc.), in connection with the Reverse Takeover of Crosswinds Holdings, completed a private placement offering of 4,420,647 subscription receipts at a price of $1.40 per subscription receipt for aggregate gross proceeds of $6,188,906.

On completion of the Reverse Takeover, the subscription receipts were exchanged for common shares of the Company.

Biomind Labs Inc. (OTCMKTS:CRSWF) is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. 

The Aird & Berlis’ team comprised of Richard Kimel (Picture), Marek Lorenc, Danny Kharazmi and David Mba (Capital Markets/M&A). 

Involved fees earner: Danny Kharazmi – Aird & Berlis LLP; Richard Kimel – Aird & Berlis LLP; Marek Lorenc – Aird & Berlis LLP; David Mba – Aird & Berlis LLP;

Law Firms: Aird & Berlis LLP;

Clients: Biomind Labs Inc.;

Author: Martina Bellini